FDA Reviews Trexima for Treatment of Migraines

Susan Farley
Published Online: Thursday, December 1, 2005

GlaxoSmithKline and POZEN Inc announced that the drug Trexima will be reviewed by the FDA for the acute treatment of migraine headaches. The companies have proposed Trexima as the brand name for their combination of sumatriptan succinate (Imitrex) and naproxen sodium (Aleve, for example) in a single-tablet form. Pending approval by the FDA, Trexima could be available to the public by the second half of 2006.

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues